Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

Christian Rolfo*, Helen Swaisland, Karin Leunen, Annemie Rutten, Patricia Soetekouw, Sarah Slater, Henk M. W. Verheul, Anitra Fielding, Karen So, Wendy Bannister, Emma Dean

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of a parts per thousand currency sign400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer. This Phase I, open-label, randomized trial investigates the effect of food on the pharmacokinetics of olaparib in patients with refractory/resistant advanced solid tumors. In Part A, a three-period crossover study, patients received a single oral dose of olaparib 400 mg (8 x 50 mg capsules) in three prandial states: fasted, a high-fat meal or a standard meal (with a 5-14 day washout). Blood samples for pharmacokinetic (PK) assessments were taken pre-dose and up to 72 h post-dose. After completing Part A, patients could enter Part B, where they would receive olaparib 400 mg BID. 32 patients were randomized; 31 contributed to the PK statistical analysis and entered Part B. The presence of food slowed the rate of absorption (time to maximal plasma concentration [t (max)] was delayed by 2 h). Maximum plasma concentration (C (max)) was increased by 10% following a standard meal and was unchanged with a high-fat meal (ratio of geometric means [90% confidence interval (CI)]: 1.10 [1.02-1.20] for standard and 1.00 [0.92-1.09] for high-fat meal). The extent of olaparib absorption (AUC) was increased by 20% in the fed state (ratio of geometric means: 1.21 [1.10-1.33] for standard and 1.19 [1.08-1.31] for high-fat meal). The presence of food decreased the rate and increased the extent of absorption of olaparib following oral dosing of the capsule formulation. However, the effects of food on olaparib PK were not deemed clinically important, according to predefined criteria. Safety data were consistent with the known safety profile of olaparib. AstraZeneca.
Original languageEnglish
Pages (from-to)510-522
JournalAdvances in Therapy
Issue number6
Publication statusPublished - Jun 2015


  • Food effect
  • Olaparib
  • Olaparib capsule
  • PARP inhibition
  • Pharmacokinetics
  • PK
  • Poly(ADP-ribose) polymerase (PARP) inhibitor

Cite this